… failure, and all-cause mortality. In this study, we conducted a prespecified subgroup analysis
of the DAPA-CKD … or absence of type 2 diabetes and by aetiology of chronic kidney disease. …

… slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high
… extend to CKD patients without type 2 diabetes or cardiovascular disease is unknown. The …

… kidney diseases receiving renin–angiotensin system blocking therapy have been enrolled in
the DAPA-CKD trial… with CKD Stages 2–4 and increased albuminuria, with and without T2D. …

… analyses of DAPA-CKD trial data … chronic kidney disease. The effect of dapagliflozin on
eGFR slope was more pronounced in patients with a faster rate of progression, including patients …

… patients without type 2 diabetes in the DAPA-CKD trial, we found with more precision the
albuminuria-lowering effects of dapagliflozin in patients with chronic kidney disease … in patients …

… In this prespecified analysis of the DAPA‐CKD trial, we aimed to examine whether baseline
… kidney and cardiovascular end points and on safety in patients with CKD and albuminuria. …

… New-onset type 2 diabetes was a prespecified exploratory endpoint in both DAPA-CKD and
DAPA-HF trials and is the focus of this analysis. New-onset type 2 diabetes was identified by …

… Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this
pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on …

… decline, ESKD, renal or cardiovascular death, as well as hospitalization for heart failure. In
the present analysis, the authors now show that among the 247 deaths in DAPA-CKD (ie 5.7…

… participants with chronic kidney disease with … IgA nephropathy subgroup of DAPA-CKD
are consistent with findings from other smaller, mechanistic trials of SGLT2 inhibitors in patients …